|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CIAO1 |
Gene summary for CIAO1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CIAO1 | Gene ID | 9391 |
| Gene name | cytosolic iron-sulfur assembly component 1 | |
| Gene Alias | CIA1 | |
| Cytomap | 2q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O76071 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9391 | CIAO1 | LZE2T | Human | Esophagus | ESCC | 4.08e-05 | 8.64e-01 | 0.082 |
| 9391 | CIAO1 | LZE4T | Human | Esophagus | ESCC | 1.36e-23 | 7.16e-01 | 0.0811 |
| 9391 | CIAO1 | LZE7T | Human | Esophagus | ESCC | 5.04e-21 | 9.19e-01 | 0.0667 |
| 9391 | CIAO1 | LZE8T | Human | Esophagus | ESCC | 2.01e-06 | 3.42e-01 | 0.067 |
| 9391 | CIAO1 | LZE20T | Human | Esophagus | ESCC | 6.57e-07 | 2.79e-01 | 0.0662 |
| 9391 | CIAO1 | LZE22T | Human | Esophagus | ESCC | 1.06e-07 | 6.96e-01 | 0.068 |
| 9391 | CIAO1 | LZE24T | Human | Esophagus | ESCC | 3.07e-19 | 6.59e-01 | 0.0596 |
| 9391 | CIAO1 | LZE21T | Human | Esophagus | ESCC | 1.19e-06 | 6.08e-01 | 0.0655 |
| 9391 | CIAO1 | LZE6T | Human | Esophagus | ESCC | 8.15e-12 | 5.37e-01 | 0.0845 |
| 9391 | CIAO1 | P1T-E | Human | Esophagus | ESCC | 3.33e-17 | 7.85e-01 | 0.0875 |
| 9391 | CIAO1 | P2T-E | Human | Esophagus | ESCC | 1.62e-47 | 8.56e-01 | 0.1177 |
| 9391 | CIAO1 | P4T-E | Human | Esophagus | ESCC | 6.24e-46 | 1.02e+00 | 0.1323 |
| 9391 | CIAO1 | P5T-E | Human | Esophagus | ESCC | 5.58e-36 | 7.97e-01 | 0.1327 |
| 9391 | CIAO1 | P8T-E | Human | Esophagus | ESCC | 1.65e-31 | 5.29e-01 | 0.0889 |
| 9391 | CIAO1 | P9T-E | Human | Esophagus | ESCC | 3.96e-22 | 4.66e-01 | 0.1131 |
| 9391 | CIAO1 | P10T-E | Human | Esophagus | ESCC | 4.56e-47 | 9.65e-01 | 0.116 |
| 9391 | CIAO1 | P11T-E | Human | Esophagus | ESCC | 2.56e-26 | 9.98e-01 | 0.1426 |
| 9391 | CIAO1 | P12T-E | Human | Esophagus | ESCC | 1.17e-50 | 1.00e+00 | 0.1122 |
| 9391 | CIAO1 | P15T-E | Human | Esophagus | ESCC | 1.13e-46 | 8.63e-01 | 0.1149 |
| 9391 | CIAO1 | P16T-E | Human | Esophagus | ESCC | 2.29e-38 | 7.07e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:001622611 | Esophagus | ESCC | iron-sulfur cluster assembly | 21/8552 | 26/18723 | 2.69e-04 | 1.63e-03 | 21 |
| GO:003116311 | Esophagus | ESCC | metallo-sulfur cluster assembly | 21/8552 | 26/18723 | 2.69e-04 | 1.63e-03 | 21 |
| GO:009742811 | Esophagus | ESCC | protein maturation by iron-sulfur cluster transfer | 14/8552 | 16/18723 | 6.78e-04 | 3.56e-03 | 14 |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
| GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
| GO:0016226 | Liver | HCC | iron-sulfur cluster assembly | 18/7958 | 26/18723 | 5.37e-03 | 2.24e-02 | 18 |
| GO:0031163 | Liver | HCC | metallo-sulfur cluster assembly | 18/7958 | 26/18723 | 5.37e-03 | 2.24e-02 | 18 |
| GO:00070592 | Oral cavity | OSCC | chromosome segregation | 206/7305 | 346/18723 | 5.82e-15 | 3.76e-13 | 206 |
| GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
| GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
| GO:00162262 | Oral cavity | OSCC | iron-sulfur cluster assembly | 19/7305 | 26/18723 | 4.46e-04 | 2.70e-03 | 19 |
| GO:00311632 | Oral cavity | OSCC | metallo-sulfur cluster assembly | 19/7305 | 26/18723 | 4.46e-04 | 2.70e-03 | 19 |
| GO:0097428 | Oral cavity | OSCC | protein maturation by iron-sulfur cluster transfer | 11/7305 | 16/18723 | 1.56e-02 | 4.99e-02 | 11 |
| GO:005160416 | Oral cavity | LP | protein maturation | 122/4623 | 294/18723 | 1.37e-10 | 7.72e-09 | 122 |
| GO:00070591 | Oral cavity | LP | chromosome segregation | 117/4623 | 346/18723 | 7.61e-05 | 9.91e-04 | 117 |
| GO:00162261 | Oral cavity | LP | iron-sulfur cluster assembly | 15/4623 | 26/18723 | 3.34e-04 | 3.34e-03 | 15 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CIAO1 | SNV | Missense_Mutation | novel | c.596N>T | p.Ser199Ile | p.S199I | O76071 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| CIAO1 | SNV | Missense_Mutation | c.511N>C | p.Asp171His | p.D171H | O76071 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CIAO1 | insertion | In_Frame_Ins | novel | c.584_585insTGCCAGTCCCTTGATCTTGGACTTCCCAGCCTTCAG | p.Ser195_Thr196insAlaSerProLeuIleLeuAspPheProAlaPheSer | p.S195_T196insASPLILDFPAFS | O76071 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| CIAO1 | insertion | Frame_Shift_Ins | novel | c.248_249insATTGTGT | p.Thr84LeufsTer13 | p.T84Lfs*13 | O76071 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CIAO1 | insertion | Frame_Shift_Ins | novel | c.638_639insCCTTTGCTTCCTGGGCCACACAGACACA | p.Asp214LeufsTer10 | p.D214Lfs*10 | O76071 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| CIAO1 | SNV | Missense_Mutation | novel | c.281A>C | p.Asp94Ala | p.D94A | O76071 | protein_coding | tolerated(0.06) | benign(0.068) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CIAO1 | SNV | Missense_Mutation | novel | c.622N>A | p.Arg208Ser | p.R208S | O76071 | protein_coding | deleterious(0.01) | possibly_damaging(0.656) | TCGA-AA-3956-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CIAO1 | SNV | Missense_Mutation | c.29G>A | p.Arg10His | p.R10H | O76071 | protein_coding | deleterious(0.03) | possibly_damaging(0.593) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CIAO1 | SNV | Missense_Mutation | c.854N>T | p.Ser285Leu | p.S285L | O76071 | protein_coding | deleterious(0.03) | benign(0.125) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CIAO1 | SNV | Missense_Mutation | c.532N>T | p.Arg178Trp | p.R178W | O76071 | protein_coding | tolerated(0.08) | probably_damaging(0.913) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |